Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Chemogenetics start-up launches with $19 million
by Ryan Cross
September 22, 2018
| A version of this story appeared in
Volume 96, Issue 38
Credit: Coda Biotherapeutics
Neurons expressing a fluorescent reporter protein from Coda's viral vectors.
The future of pain management may combine genetic engineering and small-molecule drugs. Coda Biotherapeutics, a South San Francisco-based start-up, has raised $19 million in series A financing to develop treatments that use gene therapy to insert engineered ion channels into sensory neurons. The neurons are subsequently turned on or off with a small molecule that binds the channel to numb pain. The technique, part of a field called chemogenetics, is based on research by Coda cofounder and University of Pittsburgh scientist Joseph C. Glorioso III.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter